Kaneko M, Kaneko S, Ohkawa H
Dept. of Pediatric Surgery, University of Tsukuba.
Gan To Kagaku Ryoho. 1991 Jun;18(7):1155-61.
Anti-tumor effects of etoposide (VP-16), vincristine and mitomycin C were evaluated with four human neuroblastoma xenograft, according to Battelle Columbus Laboratories protocol. Etoposide is one of the agents which has been reported to be effective against advanced neuroblastoma clinically, if combined with other agents. While vincristine was effective against 1 out 4 neuroblastoma xenografts, TS-N-2, with 58.1% maximum inhibition rate, etoposide was assessed ineffective as a single agent in all of the 3 xenografts used. Since etoposide had no effect on the weight gain in nude mice in this xenograft experiment, the dose of etoposide was increased two-fold against 2 xenografts, but found ineffective also in the increased dose. Mitomycin C, which has not been used in childhood malignant tumors, was effective against 2 out of 4 xenografts, TNB-9 and SK-N-AS, with 72.0% and 78.4% maximum inhibition rates, respectively.
按照巴特尔哥伦布实验室的方案，用4种人神经母细胞瘤异种移植模型评估了依托泊苷（VP - 16）、长春新碱和丝裂霉素C的抗肿瘤效果。依托泊苷是据报道若与其他药物联合使用对晚期神经母细胞瘤临床有效的药物之一。虽然长春新碱对4种神经母细胞瘤异种移植模型中的1种TS - N - 2有效，最大抑制率为58.1%，但在所用的3种异种移植模型中，依托泊苷作为单一药物被评估为无效。由于在该异种移植实验中依托泊苷对裸鼠体重增加没有影响，因此将2种异种移植模型中依托泊苷的剂量增加了两倍，但增加剂量后也发现无效。丝裂霉素C尚未用于儿童恶性肿瘤，对4种异种移植模型中的2种TNB - 9和SK - N - AS有效，最大抑制率分别为72.0%和78.4%。
